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Abstract
Background: Medical specialists are often seen as the first prescribers of new drugs. However,
the extent to which specialists influence new drug prescribing in primary care is largely unknown.
Methods: This study estimates the influence of medical specialists on new drug prescribing in
primary care shortly after market introduction. The influence of medical specialists on prescribing
of five new drugs was measured in a cohort of 103 GPs, working in 59 practices, over the period
1999 until 2003. The influence of medical specialists on new drug prescribing in primary care was
assessed using three outcome measures. Firstly, the proportion of patients receiving their first
prescription for a new or reference drug from a specialist. Secondly, the proportion of GPs
prescribing new drugs before any specialist prescribes to their patients. Thirdly, we compared the
time until the GP's first own prescribing between GPs who waited for prescriptions from specialists
and those who did not.
Results:  The influence of specialists showed considerable differences among the new drugs
studied. The proportion of patients receiving their first prescription from a specialist was greatest
for the combination salmeterol/fluticasone (60.2%), and lowest for rofecoxib (23.0%). The
proportion of GPs prescribing new drugs before waiting for prescriptions from medical specialists
ranged from 21.1% in the case of esomeprazole to 32.9% for rofecoxib. Prescribing new drugs by
specialists did not shorten the GP's own time to prescribing.
Conclusion: This study shows that the influence of medical specialists is clearly visible for all new
drugs and often greater than for the existing older drugs, but the rapid uptake of new drugs in
primary care does not seem specialist induced in all cases. GPs are responsible for a substantial
amount of all early prescriptions for new drugs and for a subpopulation specialist endorsement is
not a requisite to initiate in new drug prescribing. This contradicts with the idea that the diffusion
of newly marketed drugs always follows a two-step model, with medical specialists as the
innovators and GPs as the followers.
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Background
Prescribing of newly marketed drugs is not uniformly dis-
tributed among physicians. A minority of physicians is
responsible for the majority of all early prescriptions for
new drugs shortly after market introduction [1-3]. The
interface between primary and specialist care is an impor-
tant factor in the mixture of drugs prescribed by general
practitioners (GPs) [4]. In healthcare systems where GPs
function as gatekeepers for accessing specialist care, like in
the UK and the Netherlands, referral of patients and
repeat prescribing of specialist-initiated prescription are
important mechanisms through which specialists influ-
ence GP prescribing [5,6].
Two studies found GPs' prescribing behaviour to be a
derivative of specialist prescribing by showing that 60–
66% of all drugs prescribed by GPs were initiated by med-
ical specialists [7,8]. However, these studies did not differ-
entiate between new and old drugs. Tamblyn et al. found
no indications that repeat prescribing of specialist pre-
scriptions influenced the GP's prescribing of new drugs
[2]. In addition, Robertson et al. noted that prescriptions
for more recently introduced drugs were not more likely
to have been specialist initiated than older drugs [9]. So
despite the acknowledged impact that specialists have on
the prescribing of existing drugs by GPs, little data are
available when it comes newly marketed drugs.
Better understanding of the interplay between primary
and specialist care, and thereby the mechanisms by which
new drug diffuse into medical practice, contribute to the
discussion on ensuring patient safety and a sustainable
cost-containment in health care [10,11]. Therefore, the
aim of this study was to estimate the influence of medical
specialists on new drug prescribing in primary care shortly
after market introduction. We were interested in three
questions. Firstly, are newly marketed drugs in primary
care mainly prescribed by medical specialists during the
early post-marketing period? Secondly, how many GPs
start prescribing new drugs before medical specialists do




In this study we used dispensing data from patients of 103
GPs who participated in the second Dutch national survey
of general care (DNSGP-2), conducted by NIVEL (Nether-
lands Institute for Health Services Research) in 2001
[12,13]. The 103 GPs worked in 59 non-dispensing prac-
tices in all 12 provinces of the Netherlands. Dispensing
data were collected by the network of the Foundation for
Pharmaceutical Statistics (SFK) and covered the period
1999 until 2003 [14]. Because virtually all patients in the
Netherlands designate a single pharmacy to fill prescrip-
tions from both GPs and medical specialists, dispensing
data provide an almost complete account of drug expo-
sure in time [15].
Study design
For this study we selected five new drugs as study cases,
namely the combination of a long-acting bronchodilator
and inhalation corticosteroid (ICS) salmeterol/flutica-
sone, the cyclo-oxygenase-2 inhibitor rofecoxib, the pro-
ton pump inhibitor esomeprazole, the long-acting
anticholinergic bronchodilator tiotropium, and the lipid
lowering HMG-CoA reductase inhibitor rosuvastatin.
Table 1 shows relevant characteristics of these case study
drugs.
With the introduction of a new drug, physicians can either
treat a patient with the tried and proven existing drug (if
available) or the newly introduced drug. As reference
drugs for the selected study case drugs we used all long-
acting beta-2 antagonists and ICS for the combination sal-
meterol/fluticasone, all ipratropium bromide containing
products for tiotropium, all non-steroidal anti-inflamma-
tory drugs (NSAIDs) (excl. low-dose aspirin) for
rofecoxib, all proton pump inhibitors for esomeprazole
and all HMG-CoA reductase inhibitors for rosuvastatin.
All five new drugs showed rapid market introduction and
were listed within one year after market introduction in
the top 10 drugs associated with the fastest growing
expenditures in the Netherlands [14]. All drugs were fully
reimbursed by all health insurance companies and could
be prescribed without limitation by both GPs as medical
specialists.
Table 1: Characteristics of the five newly marketed drugs included in the study
New drug (Brand name) Market introduction Main indication Reference group
Salmeterol/fluticasone (Seretide/Advair) 1999, May Asthma/COPD* Long acting β2-agonist and ICS
Rofecoxib (Vioxx) 2000, Apr Rheumatoid arthritis NSAIDs excl. low-dose aspirin
Esomeprazole (Nexium) 2000, Nov Gastro-oesophageal reflux Proton pomp inhibitors
Tiotropium (Spiriva) 2002, Jun COPD Ipratropiumbromide containing products
Rosuvastatin (Crestor) 2003, Mar Hypercholesterolemia HMG CoA reductase inhibitors
*COPD: Chronic Obstructive Pulmonary DiseaseBMC Health Services Research 2009, 9:6 http://www.biomedcentral.com/1472-6963/9/6
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For this study we included patients starting on a new or a
reference drug during the first six months after market
introduction. We included both new starters and switch-
ers. The date of the patient's first prescription for either the
new or reference drug was termed the index date. Starting
was defined as receiving a prescription for a new or refer-
ence drug and no prescription for that same drug during
the six months before the index date. Patients in whom
dispensing follow-up of less than six months was present
were excluded. Market introduction was defined as the
date of the first prescription for the new drug in the data-
base.
Main outcome measurements
We recorded the type of physician (GP or medical special-
ist) using the patient's prescription for a new or reference
drug on the index date. To answer the first research ques-
tion, we calculated per new drug the proportion of
patients receiving their first prescription for a new drug
from a medical specialist out of the total number of
patients receiving the drug from both GPs and medical
specialists. The same proportion was calculated for the ref-
erence groups to calculate a relative rate. To answer the
second research question of how many GPs start prescrib-
ing new drugs before waiting for any prescriptions of med-
ical specialists, we calculated the proportion of GPs that
started prescribing the new drug before any of their
patients received the drug from a medical specialist. To
answer the third research question we calculated for each
GP the time between market introduction and the date on
which the GP prescribed the new drug for the fist time to
a patient who never used the drug before. We compared
the time to prescribing between GPs that initiate therapy
before one of their patients received the drug from a med-
ical specialist and GPs that waited for specialist to pre-
scribe first before prescribing themselves.
Results
In total 1,687 patients received one of the five new drugs
during the first six months after market introduction.
Most patients received rofecoxib (N = 596), followed by
tiotropium (N = 556), rosuvastatin (N = 212), the combi-
nation salmeterol/fluticasone (N = 171) and esomepra-
zole (N = 152). The average age was 61.7 years (SD 15.3
years) and 57.2% was female. Overall 16,797 patients
received a drug from the reference groups (mean age 51.9
years (SD 18.7); 58.8% female). Complete dispensing
data were available for 80 GPs for the combination salm-
eterol/fluticasone. The number of included GPs for
rofecoxib was 85, 90 for esomeprazole, 98 for tiotropium,
and 94 for rosuvastatin.
During the first six months following market launch,
three drugs were more frequently prescribed by GPs than
by medical specialists. Most patients starting on rofecoxib,
esomeprazole, or rosuvastatin, received their first pre-
scription from their own GP. The proportion of patients
receiving their first prescription from a GP was 77.0% for
rofecoxib, 65.1% for esomeprazole, and 58.0% for rosuv-
astatin. On the other hand, tiotropium and salmeterol/
fluticasone were more frequently initiated by medical spe-
cialists. Of the patients starting on tiotropium, 52.7%
Table 2: New drug prescribing on patient level.
New drug N (%) Reference drug N (%) Relative Rate (95% CI)
Salmeterol/fluticasone
Medical specialist 103 (60.2%) 302 (16.9%) 3.56 (3.03–4.17)
GP 68 (39.8%) 1,481 (83.1%) Ref.
Rofecoxib
Medical specialist 137 (23.0%) 1,445 (13.0%) 1.77 (1.51–2.06)
GP 459 (77.0%) 9,656 (87.0%) Ref.
Esomeprazole
Medical specialist 53 (34.9%) 424 (19.6%) 1.78 (1.41–2.25)
GP 99 (65.1%) 1,741 (80.4%) Ref.
Tiotropium
Medical specialist 293 (52.7%) 123 (14.5%) 3.64 (3.03–4.36)
GP 263 (47.3%) 726 (85.5%) Ref.
Rosuvastatin
Medical specialist 89 (42.0%) 355 (39.5%) 1.06 (0.89–1.27)
GP 123 (58.0%) 544 (60.5%) Ref.
Overall
Medical specialist 675 (40.0%) 2,649 (15.8%) 2.53 (2.37–2.71)
GP 1,012 (60.0%) 14,148 (84.2%) Ref.
Number of patients receiving their first prescription for a new or a reference drug from a medical specialist or GP six months after market 
introduction.BMC Health Services Research 2009, 9:6 http://www.biomedcentral.com/1472-6963/9/6
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received their first prescription from a specialist. The pro-
portion was 60.2% for salmeterol/fluticasone. Table 2
shows for each new drug the number of patients receiving
a new or reference drug and the corresponding likelihood
of receiving a new drug from a specialist compared to a
reference drug. Except for rosuvastatin, receiving a new
drug from a specialist was more likely than receiving a ref-
erence drug from a GP. The relative rate was greatest for
tiotropium (RR 3.64; 95% CI 3.03–4.36) and salmeterol/
fluticasone (RR 3.56; 95% CI 3.03–4.17). For rosuvasta-
tin, no difference was observed (RR 1.06 95% CI 0.89–
1.27).
The proportion of GPs with at least one patient in their
practice that received a new drug during the first six
months after market introduction ranged from 53.3% for
esomeprazole to 94.9% for tiotropium (Table 3). Not all
GPs initiated in prescribing the new drugs themselves. The
proportion of GPs starting therapy ranged from 30.0% for
esomeprazole to 66.3% for tiotropium. A substantial pro-
portion of GPs that started prescribing new drugs did so
before any of their own patients received a prescription
from a specialist. The proportion of GPs prescribing new
drugs before a specialist prescription ranged from 21.1%
for esomeprazole to 32.9% for rofecoxib.
The time between market introduction and actual pre-
scribing of the different new drugs showed considerable
variation among GPs (Table 4). For all new drugs, the
average time to prescribing was shorter (not significantly)
for GPs that started prescribing before one of their
patients received a prescription from a specialist com-
pared to GPs waiting for a prescription from a medical
specialist.
Discussion
The primary objective of this study was to estimate the
influence of medical specialists on new drug prescribing
in primary care shortly after market introduction. This
study shows that the influence of medical specialists is
clearly visible for all new drugs and often greater than for
the existing older drugs, but the rapid uptake of new drugs
in primary care does not seem specialist induced by defi-
nition and very much drug dependent. A substantial pro-
portion of GPs that prescribe new drugs do so without
awaiting specialist prescribing.
The main advantage of this study was the possibility to
identify within individual GP practices patients that
received a new drug from a specialist and those receiving
a prescription from their own GP. This clear distinction
enabled us to estimate the influence of medical specialists
on new drug prescribing in primary care. In addition, we
measured the specialists' influence on new drug prescrib-
ing shortly after a new drug's market introduction in com-
parison to their influence on the prescribing of drugs from
the same therapeutic category already present on the mar-
ket.
Research on diffusion of innovations postulated a two-
step model by which innovations are adopted by a popu-
lation with innovators as the individuals who adopt first,
followed by others copying their behaviour [16,17].
Because GPs regard medical specialists as the opinion
leaders in specific medical area, they often mention spe-
cialists as the early prescribers of new drugs [18,19]. It is
therefore reasonable to assume that the diffusion of new
drugs also follows this two-steps model with medical spe-
cialists as innovators and GPs as followers. However, our
data show that this is not the case for all new drugs. Even
in the early post-marketing period in which new drug pre-
scribing by specialists should be predominant, GP pre-
scribing outweighed specialist prescribing in three out of
the five new drugs. Moreover, we noted that specialist
endorsement was not a requisite for a subpopulation of
GPs. Especially rofecoxib, and in a lesser extent rosuvasta-
tin and esomeprazole, was adopted by the majority of GPs
and 32.9% adopted before ever having seen a specialist
prescription for rofecoxib. Although the influence of spe-
cialists is clearly visible, GPs are innovators too.
The level of specialist prescribing differs per new drug.
Especially for rosuvastatin, esomeprazole, and rofecoxib,
GP were in most cases the first prescribers. On the other
Table 3: New drug prescribing on GP level.
Total number of GP GPs with at least one patient in 
their practice receiving new drug
GPs initiating therapy with 
new drugs
GPs initiating therapy without 
waiting for a specialist 
prescription
Salmeterol/fluticasone 80 59 (73.8%) 34 (42.5%) 23 (28.8%)
Rofecoxib 85 68 (80.0%) 55 (64.7%) 28 (32.9%)
Esomeprazole 90 48 (53.3%) 27 (30.0%) 19 (21.1%)
Tiotropium 98 93 (94.9%) 65 (66.3%) 26 (26.5%)
Rosuvastatin 94 61 (64.9%) 34 (36.2%) 23 (24.5%)
Number GPs with at least one patient in their practice receiving a new drug, GPs initiating therapy with a new drug, and GPs initiating new drug 
therapy without waiting for a specialist prescription.BMC Health Services Research 2009, 9:6 http://www.biomedcentral.com/1472-6963/9/6
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hand, tiotropium and the combination salmeterol/fluti-
casone were mostly initiated by specialists. This is in line
with other studies [8,9,20,21]. Robertson et al. noted in a
study among 88 Australian GPs that the proportion of
specialist-initiated prescriptions ranged from 8% to 85%
for different drug classes [9]. The smaller influence of
medical specialists for rosuvastatin, esomeprazole, and
rofecoxib may partly be explained by extensive marketing
and the relative low perceived risk associated with pre-
scribing of these drugs [22-24]. Extensive marketing cam-
paigns may have resulted in less reluctance of GPs to
adopt the new drugs fast. Moreover, rofecoxib, esomepra-
zole, and rosuvastatin are clear examples of new drugs
showing rapid uptake in primary care that is not specialist
induced.
We found that for four new drugs the likelihood of receiv-
ing a new drug from a medical specialist was significantly
higher than receiving a reference drug. Only for rosuvasta-
tin, no difference was observed. The difference between
drugs may partly be explained by differences between
patients receiving new drugs and those receiving reference
drugs. In general, medical specialists treat a different
patient mix primarily composed of more severely ill
patients that may be more likely to benefit from new
drugs [25,26]. In previous studies on new drug prescribing
we have identified channelling of new marketed drugs in
high-risk patients and those with poor a response existing
therapies [25-27].
Based on the classical model of innovation, specialist pre-
scribing could serve as a catalyst for GPs to try out the new
drugs themselves. Rapid prescribing of newly marketed
drugs by specialists could convince GPs through a learn-
ing-by-demonstration effect to adopt too. However, this is
not confirmed by our data showing that the time to first
prescription was not shorter for GPs who awaited special-
ist prescribing compared those prescribing before any of
their patients received the drug from a medical specialist.
The absence of any differences may partly be explained by
seemingly great willingness among GPs to prescribe these
newly marketed drugs.
The findings in this study need to be interpreted in light
of its limitations. Firstly, the results are based on five new
drugs and this should be taken into account when gener-
alising the results to all new drugs. Our dispensing data
contained no information on the diagnosis that may have
influenced the likelihood the patient may have referred to
medicals. Furthermore, we used dispensing data as a
proxy of physician prescribing. Patients do not fill all pre-
scriptions they receive from their physician in a pharmacy.
It is therefore possible that the dispensing data are con-
servative estimations of the real prescribing of physicians.
However, we had no indications that the filling rate of
patients was more selective for one of the five new drugs
or differed between GPs and specialists. Hospital pharma-
cies that dispense medication to patients visiting the hos-
pital is still limited in the Netherlands. It is therefore
unlikely that we missed prescriptions of specialists to the
patients of the study GPs.
Conclusion
This study shows that the influence of medical specialists
is clearly visible for all new drugs and often greater than
for older drugs, but the rapid uptake of new drugs in pri-
mary care does not seem specialist induced in all cases.
GPs are responsible for a substantial amount of all early
prescriptions for new drugs and for a subpopulation spe-
cialist endorsement is not a requisite to initiate in new
drug prescribing. This contradicts with the idea that the
diffusion of newly marketed drugs always follows a two-
step model, with medical specialists as the innovators and
GPs as the followers.
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